A gene delivery system for insect cells mediated by arginine-rich cell-penetrating peptides

Chen, Yung-Jen; Liu, Betty Revon; Dai, Yun-Hao; Lee, Cheng-Yi; Chan, Ming‐Huan; Chen, Hwei-Hsien; Chiang, Hsin‐Ju; Lee, Han-Jung

doi:10.1016/j.gene.2011.11.060

Cited by 54 publications

(48 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5). This result is consistent with our previous data obtained with the intracellular delivery of quantum dots (Liu et al, 2011) or plasmid DNA (Chen et al, 2012;Dai et al, 2011a) mediated by CPPs. Both HR9 and PR9 represent two improved SR9 derivatives, providing the superior transfection efficiency over SR9.…”

Section: Discussionsupporting

confidence: 93%

“…Accordingly, we have demonstrated that CPPs are able to efficiently deliver DNA (Chen et al, , 2012Dai et al, 2011a;Lee et al, 2011;Li et al, 2010) or RNA (Wang et al, 2007) into live cells or organisms. HR9 peptides are novel CPPs and were recently shown to deliver DNA at a higher efficiency than nona-arginine (R9) peptides did in both paramecia (Dai et al, 2011a) and insect cells (Chen et al, 2012). Further study indicated that the cellular entry for HR9/nanoparticle complexes is mediated by the direct membrane translocation pathway (Liu et al, 2011).…”

Section: Introductionmentioning

confidence: 90%

“…Recently, several studies have explored the possibility to apply CPPs as a nonviral gene delivery system (Bolhassani, 2011;Bolhassani et al, 2011;Chen et al, 2011;Dohmen and Wagner, 2011). Accordingly, we have demonstrated that CPPs are able to efficiently deliver DNA (Chen et al, , 2012Dai et al, 2011a;Lee et al, 2011;Li et al, 2010) or RNA (Wang et al, 2007) into live cells or organisms. HR9 peptides are novel CPPs and were recently shown to deliver DNA at a higher efficiency than nona-arginine (R9) peptides did in both paramecia (Dai et al, 2011a) and insect cells (Chen et al, 2012).…”

Section: Introductionmentioning

confidence: 93%

“…Three arginine-rich CPPs, SR9 (R9), HR9 (CH5-R9-H5C), and PR9 (FFLIPKG-R9), were synthesized as previously described (Chen et al, 2012;Dai et al, 2011a;Liu et al, 2011). HR9-FITC peptide containing the fluorescein isothiocyanate (FITC) at the N-terminus was chemically synthesized using solid-phase peptide synthesis and cross-linked with FITC by the FluoroTag FITC conjugation kit (Genomics, Taipei, Taiwan) according to the manufacturer's instructions (Sigma-Aldrich, Saint Louis, MO, USA).…”

Section: Preparation Of Plasmid Dna Peptide and Proteinmentioning

confidence: 99%

“…The transfection efficiency of the CPP-mediated gene delivery was determined as previously described (Chen et al, 2012;Dai et al, 2011a). The relative intensities of fluorescent images from the functional gene assay were converted and quantified using the UN-SCAN-IT software (Silk Scientific, Orem, UT, USA).…”

Section: Cpp-mediated Gene Delivery Into Human Cellsmentioning

confidence: 99%

See 4 more Smart Citations

Arginine-rich cell-penetrating peptides deliver gene into living human cells

Liu¹,

Lin²,

Chiang³

et al. 2012

Gene

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 90%

Section: Introductionmentioning

confidence: 93%

Section: Preparation Of Plasmid Dna Peptide and Proteinmentioning

confidence: 99%

Section: Cpp-mediated Gene Delivery Into Human Cellsmentioning

confidence: 99%

See 3 more Smart Citations

Arginine-rich cell-penetrating peptides deliver gene into living human cells

Liu¹,

Lin²,

Chiang³

et al. 2012

Gene

Self Cite

View full text Add to dashboard Cite

Rationally Designed Self‐Assembling Nanoparticles to Overcome Mucus and Epithelium Transport Barriers for Oral Vaccines against Helicobacter pylori

Zhang

Wang

et al. 2018

Adv Funct Materials

View full text Add to dashboard Cite

Helicobacter pylori infection is strongly associated with chronic gastritis, peptic ulcers, and gastric cancer. Antibiotic resistance in H. pylori is an increasingly serious threat to global public health. Although oral vaccination is considered to be a promising strategy for protection against H. pylori infection, the poor efficacy of oral vaccines remains a major challenge due to their poor ability to penetrate mucus and cross transepithelial absorption barriers. This study reports the development of a well‐designed nanoparticle that is electrostatically self‐assembled with antigen and cell‐penetrating peptide (CPP), and then coated with a “mucus‐inert” PEG derivative. The nanoparticles have hydrophilic and slightly negative surface properties, which confers excellent mucus‐penetrating ability. Studies demonstrate that the self‐assembled PEG derivatives gradually dissociate from the nanoparticles in mucus, exposing the CPP‐rich cores that are efficiently transepithelial transported via intracellular and paracellular pathways. Nanoparticles containing recombination urease subunit B, a candidate vaccine against H. pylori, significantly enhance systemic and mucosal antibody levels in mice, and these immune responses protect the animals from H. pylori challenge. These results suggest that the CPP‐rich PEGylated nanoparticles may be a powerful platform for building an oral vaccine to protect against gastrointestinal infection by recalcitrant H. pylori or/and other pathogenic microorganisms.

show abstract

Recent Advances in Delivery Systems for Genetic and Other Novel Vaccines

et al. 2022

View full text Add to dashboard Cite

including yellow fever, polio, diphtheria, rubella, smallpox, mumps, and measles in humans; and equine infectious anemia, classic swine fever, and cattle plague in animals. The successful prevention of these diseases has saved millions of lives, as well as time and efforts in health care. However, conventional vaccines are usually not effective as therapeutic measures, and often fail to provide sufficient protections against some diseases. Therefore, many major diseases, such as the malaria, tuberculosis, dengue, human immunodeficiency virus (HIV) infections, and cancer, still lack effective vaccines, and developing vaccines for them remains challenging. [5][6][7] Though many autoimmune diseases are also difficult to vaccinate, we excluded this type of diseases in the review due to their highly variable and unique mechanisms.There are various factors that may influence the outcomes of vaccines. An important discovery of modern immunology is that robust cellular immune responses with strong CD8 + T cell activities may significantly improve vaccination outcome against some of these hard-to-vaccinate diseases. This is particularly the case when the pathogens can lurk in infected cells for a long period of time (e.g., HIV) or the cells themselves became malfunctional (e.g., cancer). However, conventional vaccines often suffer from imprecise control of vaccine activity in vivo (e.g., targeted accumulation and selective cell uptake) which leads to insufficient/inappropriate immune responses or short immune memory; hence, they may become less effective in these situations. [7][8][9] Besides, rapid vaccine development, targeted epitope optimization, and other novel strategies are regarded to be important for successful prevention of infections from viral pathogens with high mutation rates (e.g., the highly variable influenza virus) which often quickly become resistant to existing vaccines. [10,11] With the advances in biological and pharmaceutical technologies, a series of new vaccines have been developed, including the famous subunit vaccines (including bioengineered protein, protein fragments, and peptides) and genetic vaccines (normally DNA-and RNA-based vaccines). These alternative vaccines provide new possibilities for preventing hard-to-vaccinate diseases by using carefully selected components of the pathogens or diseased cells as vaccine immunogens based on in-depth understanding of the immune response activation processes. More specifically, characteristic proteins/peptides Vaccination is one of the most successful and cost-effective prophylactic measures against diseases, especially infectious diseases including smallpox and polio. However, the development of effective prophylactic or therapeutic vaccines for other diseases such as cancer remains challenging. This is often due to the imprecise control of vaccine activity in vivo which leads to insufficient/inappropriate immune responses or short immune memory. The development of new vaccine types in recent decades has created the potential for improving the prot...

show abstract

A gene delivery system for insect cells mediated by arginine-rich cell-penetrating peptides

Cited by 54 publications

References 45 publications

Arginine-rich cell-penetrating peptides deliver gene into living human cells

Arginine-rich cell-penetrating peptides deliver gene into living human cells

Rationally Designed Self‐Assembling Nanoparticles to Overcome Mucus and Epithelium Transport Barriers for Oral Vaccines against Helicobacter pylori

Recent Advances in Delivery Systems for Genetic and Other Novel Vaccines

Contact Info

Product

Resources

About